All In Biotech

Drug Trial Radar · NCT07660640

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

88

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Jul 30, 2031

Study completion Aug 30, 2031

Sponsor

Lead sponsor
Perceive Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Conditions

  • Age-Related Macular Degeneration (AMD)
  • Non-Neovascular Age-Related Macular Degeneration

Interventions

  • observational studyOther

    No intervention - observational study

  • VOY-101Biological

    One-time intravitreal injection of VOY-101.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of ocular and systemic VOY-101 related AEsTime frame: 3 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Retina Consultants of Texas

    Bellaire, Texas

  • University of Utah

    Salt Lake City, Utah

  • Sourasky Medical Center - Ichilov

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.